TABLE 3.

SUVmax Values from 8 Patients with PET-2 Scan Results Interpreted as PSMA-Positive with 89Zr-PSMA-DFO

Lesions interpreted as PSMA-positive with 89Zr-PSMA-DFO in PET-2
PatientPET findingSUVmax, day 1SUVmax, day 2SUVmax, day 3SUVmax, day 6Corresponding area with 18F-JK-PSMA-7 in PET-1, SUVmax (2 h)Corresponding area with 68Ga-PSMA-11 in PET-1, SUVmax (1 h)
1Prostate lobe right13.313.15.4
Prostate lobe left9.57.14.6
2Lung left (dignity unclear)5.76.74.1
3l.n. retroperitoneal3.16.11.4
l.n. retroperitoneal17.011.02.4
l.n. retroperitoneal14.28.91.7
l.n. supraclav. left12.16.92.2
6l.n. iliac right7.813.24.3
Os ilium left14.315.88.2
8l.n. retroperitoneal11.59.615.63.1
l.n. retroperitoneal12.28.37.26.0
l.n. supraclav. left3.22.58.12.0
10Prostate fossa right14.722.811.110.9
13l.n. iliac right7.64.55.5
14Prostate fossa left25.512.88.7
  • When one or several PSMA-positive areas were detected by 89Zr-PSMA-DFO PET, the SUVmax within the corresponding area of the 18F-JK-PSMA-7 or the 68Ga-PSMA-11 PET scan was measured. The SUVmax of 89Zr-PSMA-DFO PET-2 (first measurement) was significantly higher than the SUVmax of the PET-1 scan with 68Ga-PSMA-11 or 18F-JK-PSMA-7 in the corresponding areas (P = 0.0001, paired t test).

  • l.n. = lymph node.